OCUFEN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OCUFEN is an ophthalmic solution approved in 1986 for use in eye care. The specific mechanism of action and indications are not publicly detailed in available data, but the product is a small-molecule eye drop formulation. It is marketed by AbbVie as a branded pharmaceutical for ophthalmic conditions.
LOE Approaching
Product is approaching loss of exclusivity, indicating a mature brand with declining revenue and likely downsizing commercial infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OCUFEN offers limited career acceleration; the product is past-peak with approaching loss of exclusivity and no linked job openings. Roles on this brand are typically focused on revenue defense and managed decline rather than growth.
Brand ManagerField Sales Representative
Worked on OCUFEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.